MedTrace Logo

BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors

NCT05120271 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2025-12-05

No results posted yet for this study

Summary

This is a first-in-human (FIH), Phase 1/2, open-label, multicenter study to assess safety and determine the recommended Phase 2 dose (RP2D) of BOXR1030 administration after lymphodepleting chemotherapy (LD chemotherapy) in subjects with glypican-3 positive (GPC3+) advanced solid tumors.

Conditions

Interventions

BIOLOGICAL

CAR-GPC3 T Cells

Five dose levels each with LD chemotherapy

Sponsors & Collaborators

  • SOTIO Biotech a.s.

    collaborator INDUSTRY

  • SOTIO Biotech AG

    collaborator INDUSTRY

  • Sotio Biotech Inc.

    lead INDUSTRY

Principal Investigators

  • Pauline Duhard, Pharm.D. · SOTIO Biotech AG

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-26
Primary Completion
2025-10-24
Completion
2042-12-31
FDA Drug
Yes

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05120271 on ClinicalTrials.gov